ABUS Shares Outstanding History
Below is a table of the ABUS shares outstanding history going back to 11/15/2010:

Date ABUS Shares Outstanding
11/15/201010.34M
12/31/201010.34M
2/28/201110.34M
10/31/201112.15M
12/31/201112.15M
5/31/201214.00M
12/31/201214.31M
1/3/201314.30M
9/30/201314.55M
2/28/201419.69M
3/21/201421.95M
5/8/201422.08M
8/12/201422.11M
10/30/201422.31M
3/9/201546.57M
4/30/201554.22M
7/31/201554.33M
10/31/201554.57M
2/29/201654.63M
4/30/201654.63M
7/31/201654.80M
10/31/201654.84M
3/14/201755.02M
4/30/201755.02M
7/31/201755.03M
10/31/201755.05M
3/6/201877.66M
4/30/201878.84M
7/31/201855.40M
10/31/201855.48M
3/5/201956.12M
4/30/201956.85M
7/31/201956.85M
10/31/201956.85M
3/2/202068.94M
8/5/202080.91M
11/5/202084.91M
3/3/202195.58M
5/3/202196.39M
8/3/202199.16M
11/2/2021135.27M
3/3/2022148.64M
5/3/2022148.73M
8/2/2022149.95M

Also see: ABUS Market Cap History
ABUS YTD Return
ABUS Historical Shares Outstanding:
+25.64% CAGR
ABUS Historical Shares Outstanding: +25.64% CAGR

Mouse over chart for data details
11/15/2010 ...8/2/2022
Arbutus Biopharma is a clinical-stage biopharmaceutical company utilizing its virology expertise to develop therapeutics that target specific viral diseases. Co.'s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. Co.'s product pipeline consists of the following programs: GalNAc RNAi, which is a subcutaneously-delivered RNA interference therapeutic targeted to hepatocytes; Oral Capsid Inhibitor, which is a capsid inhibitor; Oral PD-L1 Inhibitor, which is an oral PD-L1 inhibitor that has the potential to reawaken patients' HBV-specific immune response; and Oral HBV RNA Destabilizer, which is is Co.'s oral HBV specific RNA destabilizer. We show 44 historical shares outstanding datapoints in our coverage of ABUS's shares outstanding history.

Understanding the changing numbers of ABUS shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like ABUS versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching ABUS by allowing them to research ABUS shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree ABUS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
 

ABUS Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2022, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.